Immune checkpoints are a class of regulatory molecules in the immune system that are expressed on immune cells such as T cells and can modulate the intensity and duration of immune responses.

Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.

Innovent Biologics will present a poster demonstrating the safety and efficacy of IBI343 in patients with advanced pancreatic ductal adenocarcinoma or cholangiocarcinoma.

HanAll Biopharma Launches Phase III Double-Blind, Placebo-Controlled VELOS-4 Study to Assess Tanfanercept in Treating Dry Eye Syndrome.

Diabetic macular edema (DME) is an eye complication related to diabetes, primarily affecting the macula region of the eye.

TAR-200 treatment alone achieves over 80% total remission in high-risk patients with non-muscle-invasive bladder cancer.

May 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Guangzhou Bio-gene Technologies has launched the first phase of clinical trials for its CAR-T cell therapy BG1805, which targets CLL-1.

4.29-5.5 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

selectION, Inc. has shared encouraging outcomes from its initial human Phase 1b study concerning its primary drug, si-544, targeted at individuals with atopic dermatitis.

This paper reported an innovative computational approach that successfully achieved the design and prediction of macrocyclic oligoamides composed of alpha, beta, gamma, and other non-natural amino acid backbone chemical structures.

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD).